Form 4: Alnylam Director Stuart Arbuckle Receives Equity Grant

Director Stuart A. Arbuckle was granted 671 restricted stock units and 1,441 stock options as part of annual compensation.

Summary

• Director Stuart A. Arbuckle acquired 671 restricted stock units (RSUs) on May 20, 2026.
• The director also received a grant of 1,441 stock options with an exercise price of $298.48.
• Both the RSUs and stock options vest on the earlier of the first anniversary of the grant date or the director's retirement/resignation (if within 90 days of the anniversary).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of new equity grants, though minimal in scale.

Risks

• Market price volatility affecting the value of the granted options.

Future Outlook

The equity grants are subject to standard vesting schedules tied to the director's continued service or retirement conditions.

Management Comments

• The grants were issued under the Second Amended and Restated 2018 Stock Incentive Plan.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is standard practice in the biotechnology sector to ensure long-term alignment with corporate performance and drug development milestones.

Comparison to Industry Standards

• The use of RSUs and stock options for non-employee directors is consistent with compensation structures at peer mid-to-large cap biotech firms.
• Vesting periods of one year are standard for annual director equity refresh grants.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on May 20, 2027.

Key Dates

Keywords

Alnylam Pharmaceuticals, ALNY, Director Compensation, Insider Transaction, Form 4, Equity Grant